<DOC>
	<DOCNO>NCT01767545</DOCNO>
	<brief_summary>To evaluate efficacy safety dexamethasone-implant alone combination bevacizumab . 64 eye prospectively investigate . Group 1 ( 22 CRVO 16 BRVO ) treat dexamethasone-implant alone , Group 2 ( 14 CRVO 12 BRVO ) three consecutive bevacizumab injection follow dexamethasone-implant . Recurrences treat dexamethasone-implant . Patients see preoperatively thereafter monthly interval . The primary endpoint BCVA twelve month .</brief_summary>
	<brief_title>Dexamethasone-implant Treatment RVO</brief_title>
	<detailed_description />
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Retinal Vein Occlusion</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>maximum duration symptom four month know history glaucoma corticosteroid response past Glaucoma , Diabetic Retinopathy , prior IVOM , Uveitis</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>January 2013</verification_date>
</DOC>